Cannabidiol was ineffective for manic episode of bipolar affective disorder
Abstract
The pharmacological profile of cannabidiol (CBD) has several characteristics in common with drugs known to benefit bipolar affective disorder (BAD), leading to the hypothesis that CBD may have therapeutic properties in BAD. Therefore, the aim of the present report was to directly investigate for the first time the efficacy and safety of CBD in two patients with BAD. Both patients met DSM IV criteria for bipolar I disorder experiencing a manic episode without comorbid conditions. This was an inpatient study, and the efficacy, tolerability and side effects were assessed. Both patients received placebo for the initial 5 days and CBD from the 6th to 30th day (initial oral dose of 600 mg reaching 1200 mg/ day). From the 6th to the 20th day, the first patient (a 34-year-old woman) received adjunctive olanzapine (oral dose of 10-15 mg). On day 31, CBD treatment was discontinued and replaced by placebo for 5 days. The first patient showed symptoms improvement while on olanzapine plus CBD, but showed no additional improvement during CBD monotherapy. The second patient (a 36-year-old woman) had no symptoms improvement with any dose of CBD during the trial. Both patients tolerated CBD very well and no side-effects were reported. These preliminary data suggest that CBD may not be effective for the manic episode of BAD.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Two bipolar affective disorder patients in acute manic episodes had no improvement with CBD.
“In parallel, we investigated the direct efficacy of CBD in two bipolar affective disorder (BAD) patients in acute manic episodes (145). The patients had no improvement with CBD”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [145]
Cites
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · see citing works
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · see citing works
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705 · see citing works
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515 · see citing works
Bech, P., Kastrup, M., & Rafaelsen, O. J. (1986) · PubMed · Cited by 466 · see citing works
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402 · see citing works
Del-Ben, C. M., Vilela, J. A. A., Crippa, J. A. D. S., Hallak, J. E. C., Labate, C. M., & Zuardi, A. W. (2001) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462001000300008 · Cited by 386 · see citing works
Acta Psychiatrica Scandinavica
Read, J., van Os, J., Morrison, A. P., & Ross, C. A. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/(issn)1600-0447 · Cited by 385 · see citing works
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P. F., Laguna, J., Allender, J. R., Snider, S. R., Stern, L. Z., Sandyk, R., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 324 · see citing works
Antipsychotic effect of cannabidiol.
Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995) · PubMed · Cited by 264 · see citing works
Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania
Frey, B. N., Andreazza, A. C., Ceresér, K. M. M., Martins, M. R., Valvassori, S. S., Réus, G. Z., Quevedo, J., & Kapczinski, F. P. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.01.002 · Cited by 239 · see citing works
Goodwin, F. K. (2003) · PubMed · Cited by 210 · see citing works
Cannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192 · see citing works
Cannabis use and expression of mania in the general population
Henquet, C., A, L. K. M., de Graaf, R., ten Have, M., & van Os, J. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.05.002 · Cited by 176 · see citing works
Reliability and validity of a Portuguese version of the Young Mania Rating Scale
Vilela, J. A. A., Crippa, J. A. S., Del‐Ben, C. M., & Loureiro, S. R. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005000900019 · Cited by 141 · see citing works
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential
Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051541 · Cited by 132 · see citing works
Effects of self-generated sad mood on regional cerebral activity: A PET study in normal subjects
Gemar, M. C., Kapur, S., Segal, Z. V., Brown, G. M., & Houle, S. (1996) · Depression · doi:10.1002/(sici)1522-7162(1996)4:2 · Cited by 57 · see citing works
Impact of formularies on clinical innovation.
Goodwin, F. K. (2003) · PubMed · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645 · see citing works
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., et al. (2021) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420979353 · Cited by 614 · see citing works
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · see citing works
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312 · see citing works
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., & Firth, J. (2020) · BMC Psychiatry · doi:10.1186/s12888-019-2409-8 · Cited by 253 · see citing works
A systematic review of cannabidiol dosing in clinical populations
Millar, S., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O’Sullivan, S. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14038 · Cited by 246 · see citing works
Clinicians’ Guide to Cannabidiol and Hemp Oils
VanDolah, H. J., Bauer, B. A., & Mauck, K. F. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.003 · Cited by 239 · see citing works
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?
Niesink, R. J. M., & van Laar, M. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00130 · Cited by 241 · see citing works
Endocannabinoid system and mood disorders: Priming a target for new therapies
Micale, V., Marzo, V. D., Šulcová, A., Wotjak, C. T., & Drago, F. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.002 · Cited by 222 · see citing works
Cannabidiol in Humans—The Quest for Therapeutic Targets
Zhornitsky, S., & Potvin, S. (2012) · Pharmaceuticals · doi:10.3390/ph5050529 · Cited by 199 · see citing works
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.002 · Cited by 170 · see citing works
Hurd, Y. L., Yoon, M. J., Manini, A. F., Hernandez, S. H., Olmedo, R., Östman, M., & Jutras‐Aswad, D. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0373-7 · Cited by 167 · see citing works
Schier, A. R. D. M., Ribeiro, N. D. C. R., Coutinho, D. C. O., Machado, S. E. D. C., Arias-Carrión, Ó., Crippa, J. A. S., Zuardi, A. W., Nardi, A. E., & Silva, A. R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140612114838 · Cited by 154 · see citing works
Endocannabinoid system dysfunction in mood and related disorders
Ashton, C. H., & Moore, P. B. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01687.x · Cited by 145 · see citing works
Elsaid, S., Kloiber, S. M., & Foll, B. L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.005 · Cited by 136 · see citing works
Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs
Vaughn, D. M., Kulpa, J., & Paulionis, L. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00051 · Cited by 119 · see citing works
Cannabidiol as a potential treatment for psychosis
Davies, C., & Bhattacharyya, S. (2019) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125319881916 · Cited by 113 · see citing works
Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Turna, J., Patterson, B. A., & Ameringen, M. V. (2017) · Depression and Anxiety · doi:10.1002/da.22664 · Cited by 101 · see citing works
Cannabidiol as a potential treatment for psychosis
Schubart, C. D., Sommer, I. E., Fusar‐Poli, P., de Witte, L. D., Kahn, R. S., & Boks, M. P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.002 · Cited by 100 · see citing works
The therapeutic role of Cannabidiol in mental health: a systematic review
Khan, R. A., Naveed, S., Mian, N., Fida, A., Raafey, M. A., & Aedma, K. K. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-019-0012-y · Cited by 97 · see citing works
Botsford, S. L., Yang, S., & George, T. P. (2020) · The American Journal on Addictions · doi:10.1111/ajad.12963 · Cited by 88 · see citing works
Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000239 · Cited by 89 · see citing works
Uso terapêutico dos canabinoides em psiquiatria
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 85 · see citing works
Yeshurun, M., Shpilberg, O., Herscovici, C., Shargian, L., Dreyer, J., Peck, A., Israeli, M., Levy-Assaraf, M., Gruenewald, T., Mechoulam, R., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.05.018 · Cited by 83 · see citing works
Valvassori, S. S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Nisihara Chagas, M. H., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106925 · Cited by 80 · see citing works
Cannabis regulatory science: risk–benefit considerations for mental disorders
Borodovsky, J. T., & Budney, A. J. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1454406 · Cited by 73 · see citing works
Kuhns, L., Kroon, E., Colyer‐Patel, K., & Cousijn, J. (2021) · Psychopharmacology · doi:10.1007/s00213-021-06001-8 · Cited by 73 · see citing works
Review: Cannabinoids as Medicinals
Khalsa, J. H., Bunt, G. C., Blum, K., Maggirwar, S. B., Galanter, M. S., & Potenza, M. N. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00438-3 · Cited by 72 · see citing works
The therapeutic potential of purified cannabidiol
O’Sullivan, S. E., Jensen, S. S., Nikolajsen, G. N., Bruun, H. Z., Bhuller, R., & Hoeng, J. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00186-9 · Cited by 56 · see citing works
Grotenhermen, F., Russo, E. B., & Zuardi, A. W. (2017) · Cannabis and Cannabinoid Research · doi:10.1089/can.2016.0036 · Cited by 56 · see citing works
Colizzi, M., Ruggeri, M., & Bhattacharyya, S. (2020) · Frontiers in Psychology · doi:10.3389/fpsyg.2020.00833 · Cited by 50 · see citing works
The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis
Hahn, B. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx105 · Cited by 47 · see citing works
Ryan, D., McKemie, D. S., Kass, P. H., Puschner, B., & Knych, H. K. D. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3028 · Cited by 46 · see citing works
Is there a role for cannabidiol in psychiatry?
Khoury, J. M., das Neves, M. D. C. L., Roque, M. A. V., Queiroz, D. A. D. B., de Freitas, A. A. C., de Fátima, Â., Moreira, F. A., & Garcia, F. D. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1285049 · Cited by 45 · see citing works
Cannabinoids and their therapeutic applications in mental disorders
Scherma, M., Muntoni, A. L., Riedel, G., Fratta, W., & Fadda, P. (2020) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2020.22.3/pfadda · Cited by 38 · see citing works
Pinto, J. V., Saraf, G., Frysch, C., Vigo, D., Keramatian, K., Chakrabarty, T., Lam, R. W. M., Kauer‐Sant’Anna, M., & Yatham, L. N. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719895195 · Cited by 36 · see citing works
Therapeutic Applications of Cannabinoids in Cardiomyopathy and Heart Failure
Garza-Cervantes, J. A., Ramos-González, M. R., Lozano, O., Carlos Jerjes-Sánchez, D., & García‐Rivas, G. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4587024 · Cited by 38 · see citing works
Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain
Porter, B., Marie, B. S., Milavetz, G., & Herr, K. (2021) · Journal of Gerontological Nursing · doi:10.3928/00989134-20210610-02 · Cited by 33 · see citing works
Cannabidiol (CBD) treatment improves spatial memory in 14-month-old female TAU58/2 transgenic mice
Kreilaus, F., Przybyla, M., Ittner, L. M., & Karl, T. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113812 · Cited by 31 · see citing works
Bipolar disorder and the endocannabinoid system
Arjmand, S., Behzadi, M., Kohlmeier, K. A., Mazhari, S., Sabahi, A., & Shabani, M. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.21 · Cited by 29 · see citing works
Saleska, J. L., Bryant, C., Kolobaric, A., D’Adamo, C. R., Colwell, C. S., Loewy, D. H., Chen, J., & Pauli, E. K. (2023) · Journal of the American Nutrition Association · doi:10.1080/27697061.2023.2203221 · Cited by 29 · see citing works
Feo, G. D., Case, A. A., Crawford, G. B., Hui, D., To, J., Sbrana, A., Alderman, B., Mukhopadhyay, S., Bouleuc, C., Amano, K., et al. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07628-3 · Cited by 30 · see citing works
Rice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 27 · see citing works
Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing
Cairns, E. A., Benson, M. J., Bedoya‐Pérez, M. A., Macphail, S. L., Mohan, A., Cohen, R., Sachdev, P. S., & McGregor, I. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142680 · Cited by 25 · see citing works
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Dammann, I., Rohleder, C., & Leweke, F. M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2228-6118 · Cited by 23 · see citing works
Abuso de cannabis em pacientes com transtornos psiquiátricos: atualização para uma antiga evidência
Diehl, A., Cordeiro, D. C., & Laranjeira, R. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500007 · Cited by 19 · see citing works
A critical review of cannabis in medicine and dentistry: A look back and the path forward
Abidi, A. H., Alghamdi, S. S., & Derefinko, K. J. (2022) · Clinical and Experimental Dental Research · doi:10.1002/cre2.564 · Cited by 19 · see citing works
Existing and emerging pharmacological approaches to the treatment of mania: A critical overview
Sparacino, G., Verdolini, N., Vieta, E., & Pacchiarotti, I. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01928-8 · Cited by 12 · see citing works
Sanches, R. F., & Marques, J. M. D. A. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000200014 · Cited by 9 · see citing works
A Holistic Review of Cannabis and Its Potential Risks and Benefits in Mental Health
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Psychiatry International · doi:10.3390/psychiatryint6030092 · Cited by 11 · see citing works
A drug discovery case history of ‘delta-9-tetrahydrocannabinol, cannabidiol’
Tănăsescu, R., Rog, D. J., & Constantinescu, C. S. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.560935 · Cited by 7 · see citing works
Saleska, J. L., Pauli, E. K., Rezvan, P. H., Cobb, O. M., Chen, J., Thorogood, P. W., Bačkonja, M., Colwell, C. S., Loewy, D. H., Russo, E. B., et al. (2022) · Integrative Medicine Reports · doi:10.1089/imr.2022.0081 · Cited by 5 · see citing works
Saleska, J. L., Bryant, C., Kolobaric, A., Colwell, C. S., Loewy, D. H., Chen, J., & Pauli, E. K. (2023) · medRxiv · doi:10.1101/2023.01.20.23284842 · Cited by 3 · see citing works
Cannabidiol in the Treatment of Mood Disorders
Pinto, J. V., Ziak, M. L., Schaffer, A., & Yatham, L. N. (2022) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-022-00265-3 · Cited by 2 · see citing works
The Use of Medical Marijuana in the Treatment of Psychiatric Disorders
Tellioğlu, T., & Tellioğlu, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00105-8 · Cited by 2 · see citing works
Villalobos-González, C. E., Gómez‐Carmona, C. D., Sánchez‐Ureña, B., Azofeifa-Mora, C., & Rojas‐Valverde, D. (2024) · Preprints.org · doi:10.20944/preprints202405.0517.v1 · Cited by 1 · see citing works
Cannabinoids and bipolar disorder
Braga, R. J., Abdelmessih, S., Tseng, J., & Malhotra, A. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00009-6 · Cited by 1 · see citing works
Treatments with cannabinoids and brain development
Schönhofen, P., de Vargas, D. M., Parsons, R. B., & Klamt, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817988-8.00036-1 · Cited by 1 · see citing works
Charrette, A., Akingbasote, J. A., Guthrie, N., & Hilmas, C. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821038-3.00039-2 · Cited by 1 · see citing works
Cannabidiol: An Overview of its Antipsychotic Properties
Peres, F. F., de Almeida, V., & Abílio, V. C. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00092-2 · Cited by 1 · see citing works
Cannabinoids and Mental Health Risks
MacCallum, C. A., de Freitas, L., & Lu, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-69186-8_33 · Cited by 1 · see citing works
Diehl, A., Cordeiro, D. C., & Laranjeira, R. (2010)
Cannabidiol – decades of research and current clinical uses
Rădoi, V., & Cicu, G. (2019) · Psihiatru ro · doi:10.26416/psih.59.4.2019.2605
The Long-Term Effect of CBD Crystals and CBD Oil on Depressive-Associated Rat Behaviors
Yang, J., & Liu, S. (2020) · Journal of Emerging Investigators · doi:10.59720/20-150
Cannabidiol Therapy for Comorbid Schizophrenia and Addiction: A Guide for Clinical PracticePreprint
Maj, J., & Francis, A. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4857098
Botsford, S. L., Yang, S., & George, T. P. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.25023010
- Authors
- Zuardi, A., Crippa, J., Dursun, S., Morais, S., Vilela, J., Sanches, R., & Hallak, J.
- Affiliations
- Universidade de São Paulo (BR)
- Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
- Department of Neuropsychiatry and Medical Psychology, Faculty of Medicine, University of São Paulo, Ribeirão Preto, São Paulo, Brazil
- Corresponding author
- Zuardi, AW
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2008-09-18
- Volume
- 24
- Issue
- 1
- Pages
- 135-137
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2052694761
- Cited by
- 72
- References
- 18
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 9 · 2019: 9 · 2018: 3 · 2017: 7 · 2015: 3 · 2014: 1 · 2013: 2 · 2012: 4
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- cannabidiol, bipolar disorder, manic episodes, bipolar I disorder, olanzapine, adjunctive therapy, monotherapy, treatment efficacy, tolerability, adverse effects
- MeSH terms
- Olanzapine, Adult, Benzodiazepines, Bipolar Disorder, Cannabidiol, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Antipsychotic Agents, Single-Blind Method, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
